DocGo director receives 150,000 RSUs under 2021 stock plan
DocGo Inc. director Michael J. Burdiek received 150,000 shares of common stock in the form of restricted stock units (RSUs) on December 12, 2025.
Rhea-AI Filing Summary
DocGo Inc. director Michael J. Burdiek received 150,000 shares of common stock in the form of restricted stock units (RSUs) on December 12, 2025. These RSUs were granted at a price of $0 under DocGo's 2021 Stock Incentive Plan and are scheduled to vest on December 12, 2026, subject to the plan's terms. Each RSU represents the right to receive one share of DocGo common stock upon vesting. Following this grant, Burdiek beneficially owns 791,560 shares of DocGo common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 150,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2021 Stock Incentive Plan (the "Plan") that will vest on December 12, 2026, subject to the terms of the Plan. Each RSU represents the right to receive, upon vesting, one share of Common Stock, subject to the terms of the Plan.
FAQ
What insider equity grant did DocGo Inc. (DCGO) report for Michael J. Burdiek?
DocGo reported that director Michael J. Burdiek received 150,000 restricted stock units (RSUs) of DocGo common stock on December 12, 2025 at a price of $0.
When do Michael J. Burdiek’s newly granted DocGo (DCGO) RSUs vest?
The 150,000 RSUs granted to Michael J. Burdiek are scheduled to vest on December 12, 2026, subject to the terms of DocGo's 2021 Stock Incentive Plan.
What does each RSU granted to Michael J. Burdiek by DocGo Inc. (DCGO) represent?
Each restricted stock unit (RSU) granted to Michael J. Burdiek represents the right to receive one share of DocGo common stock upon vesting, subject to the plan's terms.
Under which plan were Michael J. Burdiek’s DocGo (DCGO) RSUs granted?
The 150,000 RSUs granted to Michael J. Burdiek were issued under DocGo's 2021 Stock Incentive Plan, as described in the report.
AI-generated analysis. How Rhea-AI works. Not financial advice.